Sanofi Expands China Footprint In OTC And Rx Markets With BMP Sunstone Acquisition
This article was originally published in PharmAsia News
Executive Summary
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys
You may also be interested in...
Bayer Doubles OTC Presence In China With Dihon Acquisition
Bayer AG acquired its second Chinese over-the-counter company to scale up amid the country’s OTC consolidation trend.
Bayer Doubles OTC Presence In China With Dihon Acquisition
Bayer AG acquired its second Chinese over-the-counter company to scale up amid the country’s OTC consolidation trend.
Seeking New Opportunities For Traditional Chinese Medicine
A joint venture between Nestle Health and Hutchison China MediTech is amid an ongoing Phase III trial hoping to validate traditional Chinese medicine for Western health care systems. New reports of TCM contamination in China offer a glimpse of opportunity for Western entries.